81 related articles for article (PubMed ID: 2977981)
1. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses.
Vittoria A; Messa GL; Frigerio C; Celasco G; Auteri A
Int J Tissue React; 1988; 10(4):261-6. PubMed ID: 2977981
[TBL] [Abstract][Full Text] [Related]
2. [Effects of 2 single oral doses of mesoglycan on the coagulation-fibrinolysis system in man. A pharmacodynamic study].
Messa G; Blardi P; La Placa G; Puccetti L; Ghezzi A
Recenti Prog Med; 1995; 86(7-8):272-81. PubMed ID: 7569283
[TBL] [Abstract][Full Text] [Related]
3. [Effects on the coagulation-fibrinolysis system of a single oral dose of mesoglycan at the beginning and at the end of a prolonged treatment in man].
Blardi P; Messa G; Puccetti L; La Placa G; Ghezzi A
Recenti Prog Med; 1995; 86(7-8):282-9. PubMed ID: 7569284
[TBL] [Abstract][Full Text] [Related]
4. Sulodexide oral administration influences blood viscosity and fibrinolysis.
Crepaldi G; Rossi A; Coscetti G; Abbruzzese E; Calveri U; Calabrò A
Drugs Exp Clin Res; 1992; 18(5):189-95. PubMed ID: 1490434
[TBL] [Abstract][Full Text] [Related]
5. Mesoglycan exerts its fibrinolytic effect through the activation of annexin A2.
Belvedere R; Morretta E; Pessolano E; Novizio N; Tosco A; Porta A; Whiteford J; Perretti M; Filippelli A; Monti MC; Petrella A
J Cell Physiol; 2021 Jul; 236(7):4926-4943. PubMed ID: 33284486
[TBL] [Abstract][Full Text] [Related]
6. [Mesoglycan and fibrinolysis: therapeutic activity of oral mesoglycan in venous thrombosis. A short-term clinical, biological and instrumental study].
Vittoria A; Cappelli R; Messa GL; Auteri A
Minerva Med; 1986 Oct; 77(40):1867-72. PubMed ID: 2946002
[No Abstract] [Full Text] [Related]
7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
9. [Effectiveness of mesoglycan therapy in patients with ischemia of the lower limbs. Preliminary results of a new therapeutic protocol].
Raso AM; Maggio D; Trogolo M; Rispoli P; Sandrone N; Pezzuto D; Bellan A; Melloni CD
Minerva Cardioangiol; 1997; 45(7-8):383-92. PubMed ID: 9463174
[TBL] [Abstract][Full Text] [Related]
10. [Fibrinolytic system of animals repeatedly and chronically administered plasminogen tissue activator].
Shimonaeva EE; Liutova LV; Andreenko GV
Vopr Med Khim; 1981; 27(6):823-8. PubMed ID: 7199779
[TBL] [Abstract][Full Text] [Related]
11. [Activation of the fibrinolytic system following subcutaneous administration and inhalation of heparin].
Psuja P; Tokarz A; Turowiecka Z; Sowier J; Zawilska K
Pol Tyg Lek; 1993 Feb 1-8; 48(5-6):105-8. PubMed ID: 8361902
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic activity in blood and lungs of rats treated with monocrotaline pyrrole.
Schultze AE; Roth RA
Toxicol Appl Pharmacol; 1993 Jul; 121(1):129-37. PubMed ID: 7687795
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of mesoglycan topical treatment of leg ulcers in subjects with chronic venous insufficiency].
La Marca G; Pumilia G; Martino A
Minerva Cardioangiol; 1999 Sep; 47(9):315-9. PubMed ID: 10630070
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
16. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
17. Vitamin E improves fibrinolytic activity in patients with coronary spastic angina.
Miyamoto S; Kawano H; Takazoe K; Soejima H; Sakamoto T; Hokamaki J; Yoshimura M; Nakamura H; Yodoi J; Ogawa H
Thromb Res; 2004; 113(6):345-51. PubMed ID: 15226088
[TBL] [Abstract][Full Text] [Related]
18. [Use of a minor fibrinolytic drug (mesoglycan) in phlebitis].
Scondotto G; De Fabritiis A; Guastarobba A; Amato AC; Filippini M
Minerva Med; 1984 Jul; 75(28-29):1733-8. PubMed ID: 6236381
[TBL] [Abstract][Full Text] [Related]
19. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide.
Ceriello A; Quatraro A; Marchi E; Barbanti M; Giugliano D
Diabete Metab; 1993; 19(2):225-9. PubMed ID: 8339853
[TBL] [Abstract][Full Text] [Related]
20. The effect of dexamethasone on tissue fibrinolytic system in male and female rats.
Tsantarliotou M; Taitzoglou I; Kokolis N
In Vivo; 1999; 13(2):119-24. PubMed ID: 10363166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
